SEATTLE, WA, USA I March 21, 2025 I Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback